Log in to save to my catalogue

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's di...

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's di...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_19f084bea18e49d6b821e4355697a8ba

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter

About this item

Full title

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter

Publisher

England: BioMed Central

Journal title

Translational neurodegeneration, 2023-05, Vol.12 (1), p.24-24, Article 24

Language

English

Formats

Publication information

Publisher

England: BioMed Central

More information

Scope and Contents

Contents

In support of this, Aβ oligomer reduction in an AD mouse model leads to memory preservation [2, 3], and clinical benefit was in trials of lecanemab, which targets Aβ oligomers and protofibrils [4], in AD patients, encouraging the continued development of Aβ oligomer-targeting therapies. Given the semi-quantitative nature of the Aβ oligomer assays,...

Alternative Titles

Full title

A phase 1b randomized clinical trial of CT1812 to measure Aβ oligomer displacement in Alzheimer's disease using an indwelling CSF catheter

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_19f084bea18e49d6b821e4355697a8ba

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_19f084bea18e49d6b821e4355697a8ba

Other Identifiers

ISSN

2047-9158

E-ISSN

2047-9158

DOI

10.1186/s40035-023-00358-w